Month: May 2024

Brink’s Announces Strong First-Quarter Results and Affirms Full Year Guidance

Written by Customer Service on May 8, 2024. Posted in Public Companies.

Record First Quarter Revenue Reflecting 4% Growth and 12% Organic GrowthGAAP net income up 229% to $49M and record adjusted EBITDA up 15% to $218MGAAP EPS up 263% to $1.09 and non-GAAP EPS up 20% to $1.52TTM GAAP Net Cash from Operations up 56% to $800M: non-GAAP Free Cash Flow up 61% to $363M RICHMOND, Va., May 08, 2024 (GLOBE NEWSWIRE) — The Brink’s Company (NYSE:BCO), a leading global provider of cash and valuables management, digital retail solutions (DRS), and ATM managed services (AMS), today announced first-quarter results. Mark Eubanks, president and CEO, said: “In the first quarter we delivered robust organic revenue growth across all segments and customer offerings. Organic growth in AMS and DRS accelerated sequentially and was up 18% year-over-year as customer demand continues to build for our value-added solutions....

Arbor Biotechnologies Announces Acquisition of Serendipity

Written by Customer Service on May 8, 2024. Posted in Mergers And Acquisitions.

Serendipity brings proprietary gene editing assets from the lab of gene editing pioneer Feng Zhang, bolstering Arbor’s diverse toolbox of novel, next-generation editors and expanding potential therapeutic applications in reverse transcriptase-based editing and insertion of large regions of DNA CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) — Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the acquisition of Serendipity Biosciences, a private biotechnology company focused on the discovery of unique gene editing technologies. Serendipity’s novel editing technologies were discovered in the lab of leading gene editing researcher and Arbor Biotechnologies co-founder, Feng Zhang, of the McGovern Institute for Brain Research at MIT and the Broad...

Immunocore reports first quarter financial results and provides a business update

Written by Customer Service on May 8, 2024. Posted in Earnings Releases And Operating Results.

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, May 8, 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2024 and provided...

Kojamo plc Interim Report 1 January–31 March 2024

Written by Customer Service on May 8, 2024. Posted in Earnings Releases And Operating Results.

Kojamo plc Stock Exchange Release, 8 May 2024 at 2.00 p.m. EEST Kojamo plc Interim Report 1 January–31 March 2024 Total revenue and net rental income increased, no significant value changes in the investment properties This is a summary of the January–March Interim Report, which is in its entirety attached to this release and can be downloaded from the company’s website at www.kojamo.fi/investors. Unless otherwise stated, the comparison figures in brackets refer to the corresponding period of the previous year. The figures in this Interim Report have not been audited. Summary of January–March 2024Total revenue increased by 4.7 per cent to EUR 113.3 (108.2) million. Net rental income increased by 1.9 per cent to EUR 60.6 (59.5) million. Net rental income was 53.5 (55.0) per cent of total revenue. Result before taxes was EUR 39.3 (24.0)...

MIND CTI Reports First Quarter 2024 Results

Written by Customer Service on May 8, 2024. Posted in Earnings Releases And Operating Results.

YOQNEAM, Israel, May 08, 2024 (GLOBE NEWSWIRE) — MIND C.T.I. LTD. – (NasdaqGM:MNDO), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product-based solutions for service providers, enterprise solutions for unified communications analytics and call accounting solutions as well as enterprise messaging solutions, today announced results for its first quarter ended March 31, 2024. The following will summarize our major achievements in the first quarter of 2024, as well as our business. The financial results can be found in the Company News section of our website at http://www.mindcti.com/company/news/ and in our Form 6-K. Financial HighlightsRevenues were $5.8 million, compared with $5.5 million in the first quarter of 2023. Operating income was $1.2 million, or 22% of total revenues, compared...

Brookfield Asset Management Announces Strong First Quarter Results

Written by Customer Service on May 8, 2024. Posted in Earnings Releases And Operating Results.

Insurance Flows and Castlelake Add $75 Billion of AUM Since Quarter End $106 Billion of Dry Powder Available to Invest BROOKFIELD, NEWS, May 08, 2024 (GLOBE NEWSWIRE) — Brookfield Asset Management Ltd. (NYSE: BAM, TSX: BAM) today announced financial results for the quarter ended March 31, 2024. Connor Teskey, President of Brookfield Asset Management stated, “We are off to a strong start in 2024 and are seeing accelerating momentum across our business as transaction activity picks up. We raised $20 billion of capital during the first quarter ($10 billion since our last earnings release), and with more than $100 billion of dry powder to invest, both the diversity of our business mix and our global footprint mean that we remain very well-positioned to capture investment opportunities.” He continued, “We recently completed a $50 billion...

AvidXchange Announces First Quarter 2024 Financial Results

Written by Customer Service on May 8, 2024. Posted in Earnings Releases And Operating Results.

Strong across-the-board year-over-year Q1’24 financial performance driven by yield expansion, transaction growth, unit cost reduction and operating expense discipline Q1’24 operating income loss of $(4.1) million more than halved versus a loss of $(17.1) million in the comparable year-ago period Q1’24 adjusted EBITDA up sharply to $17.7 million vs. $0.4 million in the comparable year-ago period Sustaining a strong balance sheet with cash and marketable securities of $443.6 million to re-invest in the core business organically and inorganically Updated 2024 business outlook reflects sustained strong execution amid macro volatilityCHARLOTTE, N.C., May 08, 2024 (GLOBE NEWSWIRE) — AvidXchange Holdings, Inc. (Nasdaq: AVDX), a leading provider of accounts payable (AP) automation software and payment solutions for middle market businesses...

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

Written by Customer Service on May 8, 2024. Posted in Earnings Releases And Operating Results.

COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP005 trial data in fourth quarter 2024, COMP006 trial top-line data expected mid-2025 Compass announces positive phase 2 COMP360 data in post-traumatic stress disorder (PTSD) Michael Gold to join Compass as Head of R&D Compass enters into additional commercial collaborations, including with Reliant Medical Group, part of Optum Care Cash position of $262.9 million at March 31, 2024 Conference call May 8 at 8:00 am ET (1:00 pm UK)LONDON, May 08, 2024 (GLOBE NEWSWIRE) — Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2024 and provided an update on recent business...

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Written by Customer Service on May 8, 2024. Posted in Public Companies.

Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5 point reduction at week 12), with change from baseline in mean SDS total score (14.4 point reduction at week 12) 81.8% response (reduction of ≥ 15 points in CAPS-5 score), 63.6% remission (total CAPS-5 ≤ 20) rates at week 4 with 77.3% response and 54.5% remission at week 12 Measures of symptom scores relative to baseline improved following a single 25mg dose administered with psychological support (n=22)LONDON, May 08, 2024 (GLOBE NEWSWIRE) — Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced top-line results...

Form 8.3 – Tyman plc

Written by Customer Service on May 8, 2024. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Jupiter Fund Management Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of Offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Tyman plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date dealing undertaken: For an opening position disclosure, state...

Month: May 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals